Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AGIO

Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances

Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted supplemental new drug application for sickle cell disease during a presentation at the 2026 R

MarketBeat · May 19

Why Is Agios Pharmaceuticals Stock Sinking Today?

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.

Benzinga · Nov 19, 2025

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.’s (NASDAQ:AGIO) supplemental New Drug Application (sNDA) of Pyrukynd (mitapivat) for adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.

Benzinga · Sep 4, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

This outdoor furniture is so good, you'll forget you're in your backyard

Your dream outdoor setup is just a few clicks away

Homes & Gardens · Jun 2, 2025

Set the scene for summer – save big on outdoor and indoor favorites at Macy's Memorial Day sale

Your home deserves a summer glow-up

Homes & Gardens · May 16, 2025

Agios Pharmaceuticals: Q1 Earnings Insights

Agios Pharmaceuticals (NASDAQ:AGIO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 5, 2022

What 5 Analyst Ratings Have To Say About Agios Pharmaceuticals

Within the last quarter, Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings:

Benzinga · Feb 24, 2022

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings For Agios Pharmaceuticals

Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:

Benzinga · Feb 22, 2022

What 4 Analyst Ratings Have To Say About Agios Pharmaceuticals

Within the last quarter, Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings:

Benzinga · Feb 22, 2022

FDA Approves Agios' Mitapivat As First Disease-Modifying Therapy For Genetic Blood Disorder

The

Benzinga · Feb 18, 2022

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March

Benzinga · Feb 17, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

420,332 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.